Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $11.00 → $5.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/12/2025 | Buy → Neutral | Ladenburg Thalmann | |
| 10/16/2023 | $13.00 | Outperform | RBC Capital Mkts |
| 1/6/2023 | $10.00 → $18.00 | Neutral → Overweight | Piper Sandler |
| 2/28/2022 | $15.50 → $10.00 | Buy | B. Riley Securities |
| 2/25/2022 | $22.00 → $20.00 | Buy | HC Wainwright & Co. |
| 7/30/2021 | $25.00 → $22.00 | Buy | HC Wainwright & Co. |
| 7/16/2021 | $19.50 | Neutral → Buy | B. Riley Securities |
ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of
ENGLEWOOD, Colo., March 3, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, March 11, 2025 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and year ended December 31, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Da
ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year.Q3 2024 net revenue of $50.0 million.Q3 2024 net income of $2.4 million; Diluted EPS $0.07.Q3 2024 cash flow from operations of $7.1 millio
10-K - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
10-Q - ZYNEX INC (0000846475) (Filer)
SC 13D/A - ZYNEX INC (0000846475) (Subject)
RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously
Ladenburg Thalmann downgraded Zynex from Buy to Neutral
RBC Capital Mkts initiated coverage of Zynex with a rating of Outperform and set a new price target of $13.00
ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of
ENGLEWOOD, Colo., March 3, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, March 11, 2025 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and year ended December 31, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Da
VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration reflects Zynex's commitment to improving access to high-quality care for our nation's veterans.
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member. The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to i
ENGLEWOOD, Colo., June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022. The appointment of Marcum LLP was made after careful consideration and an evaluation process by the Company and approved by the Board of Directors and the Audit Committee of the Company.
ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.